371 related articles for article (PubMed ID: 10830728)
1. Enhanced green fluorescent protein fusion proteins of herpes simplex virus type 1 thymidine kinase and cytochrome P450 4B1: applications for prodrug-activating gene therapy.
Steffens S; Frank S; Fischer U; Heuser C; Meyer KL; Dobberstein KU; Rainov NG; Kramm CM
Cancer Gene Ther; 2000 May; 7(5):806-12. PubMed ID: 10830728
[TBL] [Abstract][Full Text] [Related]
2. Differential cytotoxicity and bystander effect of the rabbit cytochrome P450 4B1 enzyme gene by two different prodrugs: implications for pharmacogene therapy.
Frank S; Steffens S; Fischer U; Tlolko A; Rainov NG; Kramm CM
Cancer Gene Ther; 2002 Feb; 9(2):178-88. PubMed ID: 11857036
[TBL] [Abstract][Full Text] [Related]
3. Rabbit cytochrome P450 4B1: A novel prodrug activating gene for pharmacogene therapy of hepatocellular carcinoma.
Mohr L; Rainov NG; Mohr UG; Wands JR
Cancer Gene Ther; 2000 Jul; 7(7):1008-14. PubMed ID: 10917203
[TBL] [Abstract][Full Text] [Related]
4. Transduction of human pancreatic tumor cells with vesicular stomatitis virus G-pseudotyped retroviral vectors containing a herpes simplex virus thymidine kinase mutant gene enhances bystander effects and sensitivity to ganciclovir.
Howard BD; Boenicke L; Schniewind B; Henne-Bruns D; Kalthoff H
Cancer Gene Ther; 2000 Jun; 7(6):927-38. PubMed ID: 10880025
[TBL] [Abstract][Full Text] [Related]
5. Functional expression of thymidine kinase in human leukaemic and colorectal cells, delivered as EGFP fusion protein by herpesvirus saimiri-based vector.
Hoggarth JH; Jones E; Ensser A; Meredith DM
Cancer Gene Ther; 2004 Sep; 11(9):613-24. PubMed ID: 15243631
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of tumor ablation by a selected HSV-1 thymidine kinase mutant.
Kokoris MS; Sabo P; Adman ET; Black ME
Gene Ther; 1999 Aug; 6(8):1415-26. PubMed ID: 10467366
[TBL] [Abstract][Full Text] [Related]
7. VP22 does not significantly enhance enzyme prodrug cancer gene therapy as a part of a VP22-HSVTk-GFP triple fusion construct.
Hakkarainen T; Wahlfors T; Meriläinen O; Loimas S; Hemminki A; Wahlfors J
J Gene Med; 2005 Jul; 7(7):898-907. PubMed ID: 15759279
[TBL] [Abstract][Full Text] [Related]
8. Adenovirus-mediated gene transfer of enhanced Herpes simplex virus thymidine kinase mutants improves prodrug-mediated tumor cell killing.
Wiewrodt R; Amin K; Kiefer M; Jovanovic VP; Kapoor V; Force S; Chang M; Lanuti M; Black ME; Kaiser LR; Albelda SM
Cancer Gene Ther; 2003 May; 10(5):353-64. PubMed ID: 12719705
[TBL] [Abstract][Full Text] [Related]
9. Molecular imaging with 123I-FIAU, 18F-FUdR, 18F-FET, and 18F-FDG for monitoring herpes simplex virus type 1 thymidine kinase and ganciclovir prodrug activation gene therapy of cancer.
Wang HE; Yu HM; Liu RS; Lin M; Gelovani JG; Hwang JJ; Wei HJ; Deng WP
J Nucl Med; 2006 Jul; 47(7):1161-71. PubMed ID: 16818951
[TBL] [Abstract][Full Text] [Related]
10. HIV-1 TAT protein transduction domain mediates enhancement of enzyme prodrug cancer gene therapy in vitro: a study with TAT-TK-GFP triple fusion construct.
Meriläinen O; Hakkarainen T; Wahlfors T; Pellinen R; Wahlfors J
Int J Oncol; 2005 Jul; 27(1):203-8. PubMed ID: 15942661
[TBL] [Abstract][Full Text] [Related]
11. New prodrug activation gene therapy for cancer using cytochrome P450 4B1 and 2-aminoanthracene/4-ipomeanol.
Rainov NG; Dobberstein KU; Sena-Esteves M; Herrlinger U; Kramm CM; Philpot RM; Hilton J; Chiocca EA; Breakefield XO
Hum Gene Ther; 1998 Jun; 9(9):1261-73. PubMed ID: 9650611
[TBL] [Abstract][Full Text] [Related]
12. Functional coexpression of HSV-1 thymidine kinase and green fluorescent protein: implications for noninvasive imaging of transgene expression.
Jacobs A; Dubrovin M; Hewett J; Sena-Esteves M; Tan CW; Slack M; Sadelain M; Breakefield XO; Tjuvajev JG
Neoplasia; 1999 Jun; 1(2):154-61. PubMed ID: 10933050
[TBL] [Abstract][Full Text] [Related]
13. Non-small cell lung cancer as a target disease for herpes simplex type 1 thymidine kinase-ganciclovir gene therapy.
Määttä AM; Tenhunen A; Pasanen T; Meriläinen O; Pellinen R; Mäkinen K; Alhava E; Wahlfors J
Int J Oncol; 2004 Apr; 24(4):943-9. PubMed ID: 15010834
[TBL] [Abstract][Full Text] [Related]
14. In vitro evaluation of mutant HSV-1 thymidine kinases for suicide gene therapy.
Kokoris MS; Sabo P; Black ME
Anticancer Res; 2000; 20(2A):959-63. PubMed ID: 10810381
[TBL] [Abstract][Full Text] [Related]
15. VP22 enhanced intercellular trafficking of HSV thymidine kinase reduced the level of ganciclovir needed to cause suicide cell death.
Liu CS; Kong B; Xia HH; Ellem KA; Wei MQ
J Gene Med; 2001; 3(2):145-52. PubMed ID: 11318113
[TBL] [Abstract][Full Text] [Related]
16. TK-GFP fusion gene virus vectors as tools for studying the features of HSV-TK/ganciclovir cancer gene therapy in vivo.
Pasanen T; Hakkarainen T; Timonen P; Parkkinen J; Tenhunen A; Loimas S; Wahlfors J
Int J Mol Med; 2003 Oct; 12(4):525-31. PubMed ID: 12964030
[TBL] [Abstract][Full Text] [Related]
17. Effects of bicistronic lentiviral vector-mediated herpes simplex virus thymidine kinase/ganciclovir system on human lens epithelial cells.
Yang J; Liu TJ; Lu Y
Curr Eye Res; 2007 Jan; 32(1):33-42. PubMed ID: 17364733
[TBL] [Abstract][Full Text] [Related]
18. A chimeric fusion protein of cytochrome CYP4B1 and green fluorescent protein for detection of pro-drug activating gene delivery and for gene therapy in malignant glioma.
Rainov NG; Sena-Esteves M; Fraefel C; Dobberstein KU; Chiocca EA; Breakefield XO
Adv Exp Med Biol; 1998; 451():393-403. PubMed ID: 10026902
[TBL] [Abstract][Full Text] [Related]
19. Selective radiosensitization of 9L glioma in the brain transduced with double suicide fusion gene.
Kim JH; Kolozsvary A; Rogulski K; Khil MS; Brown SL; Freytag SO
Cancer J Sci Am; 1998; 4(6):364-9. PubMed ID: 9853135
[TBL] [Abstract][Full Text] [Related]
20. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
